Metformin: From Research to Clinical Practice

• Autores: Meng H. Tan, Kara Mizokami-Stout, Mark MacEachern, Hussain Alquraini
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 45, Nº. 4, 2016 (Ejemplar dedicado a: Diabetes), págs. 819-843
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Metformin is the recommended first-line oral glucose-lowering drug initiated to control hyperglycemia in type 2 diabetes mellitus. It acts in the liver, small intestines, and skeletal muscles with its major effect on decreasing hepatic gluconeogenesis. It is safe, inexpensive, and weight neutral and can be associated with weight loss. It can reduce microvascular complication risk and its use is associated with a lower cardiovascular mortality compared with sulfonylurea therapy. It is also used to delay the onset of type 2 diabetes mellitus, in treating gestational diabetes, and in women with polycystic ovary syndrome.